Development of CRISPR as a prophylactic strategy to combat novel coronavirus and influenza
T. R. Abbott, G. Dhamdhere, Y. Liu, X. Lin, L. E. Goudy, L. Zeng, A. Chemparathy, S. Chmura, N. Heaton, R. Debs, T. Pande, D. Endy, M. La Russa, D. B. Lewis, L. S. Qi
This paper develops a CRISPR-Cas13-based strategy called PAC-MAN to inhibit SARS-CoV-2 and influenza A virus in human cells, showing it can degrade viral sequences and reduce replication.
bioRxiv · Mar 13, 2020 · PreprintBioengineering